… infections has stimulated research to identify QS inhibitors (QSIs) to defeat microbes. In this
study, four FDA-approved drugs (… used in this study: Pseudomonas aeruginosa O1 (PAO1) as …

… of colistin base has been a challenge for defining the optimum dose of … Pseudomonas
aeruginosa and Acinetobacter baumannii – including strains resistant to carbapenems. This new …

… baumannii and Pseudomonas aeruginosa. Cefiderocol is … cases in patients with underlying
health problems. To date, the … A recent analysis identified effluent flow rate during CRRT as …

… , which makes treating them challenging. Through carbapenem … Quinolones are synthetic
antimicrobial drugs with the basic … RND superfamily proteins have been identified in two efflux …

… antibiotic drugs compared to older antibiotics for the … or MDR Pseudomonas aeruginosa
was doubled with new drugs; … In addition to the medical challenges posed by these infections, …

… Unfortunately, challenges with new antibiotic discovery and … antimicrobial with activity against
Acinetobacter baumannii, … Ftortiazinon is a new antimicrobial agent administered as 300 …

… development of new antimicrobial agents is essential. Novel … Species identification was
performed at each site and … challenge to global health. There is a great need to optimize …

… most important antibacterial agents for multidrug-resistant infections of gram-… Acinetobacter
baumannii and Pseudomonas aeruginosa may gradually turn into a major clinical challenge…

… , Acinetobacter baumannii, Pseudomonas aeruginosa and … Acinetobacter baumannii is now
causing serious problems in … antibacterial agents, reducing the accumulation of antibiotics …

… highlight a broader challenge of identifying effective treatment for CRAB … antibacterial agents
for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections…